G35
Conditions
Interventions
Group 1: RRMS patients on a gluten-reduced diet
Group 2: RRMS patients with average (gluten-containing) diet.
Sponsors
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: RRMS according to McDonald 2010 criteria Age 18-60 years Stable disease course on mild/moderate DMT No other autoimmune disease or immunotherapy
Exclusion criteria
Exclusion criteria: Chronic progr. MS according to McDonald 2010 criteria Age under 18 years Age over 60 years Clinical and radiological signs of disease activity other autoimmune disease immunotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in immune cell phenotype during gluten-reduced diet. Therefore, immune cell characterisation by flow cytometry will be performed at the following points in time: Baseline: Immunophenotyping Week 12: Immunophenotyping Week 24: Immunophenotyping | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in clinical parameters of disease activity, disability, pain, and GIP excretion in urine. Therefore, the following parameter will additionally assessed: Baseline: EDSS, SF-36, Diet questionnaire, GIP in urine; Week 6: EDSS, SF-36, Diet questionnaire, GIP in urine; Week 12: EDSS, SF-36, Diet questionnaire, GIP in urine; Week 18: EDSS, SF-36, Diet questionnaire, GIP in urine; Week 24: EDSS, SF-36, Diet questionnaire, GIP in urine | — |
Countries
Germany
Contacts
Public ContactMonika Firros
Studienzentrum der Klinik für Neurologie
Outcome results
None listed